Skip to main content

datastreet.in

JM Financial calls Metropolis Healthcare ‘best-value diagnostic stock’, sees up to 27% upside

JM Financial has retained its Buy rating on Metropolis Healthcare with a target price of Rs 734, implying 27.2% upside. The brokerage calls it the cheapest among India’s leading listed diagnostic players, citing attractive valuations, network expansion, stronger B2C growth and improving margins as key drivers.

Source :- Markets-Economic Times Read More

Share it :

Leave a Reply

Your email address will not be published. Required fields are marked *